Through mechanistic studies, it was found that silencing the FCGR2A or EHD2 gene can inhibit the expression of the GBM mesenchymal marker genes CHI3L1 and CD44 (Figure 9A–9D). This evidence concerns the gene CHI3L1 and glioblastoma.